Aglepristone (Ref: RU46534) |
![]() Last updated: 12/09/2025 |
![]() |
(Not known by any other names) |
|
![]() |
|
A veterinary drug that is a synthetic, steroidal antiprogestogen related to mifepristone | |
---|---|---|
|
Used for mesalliance and termination of pregnancy | |
|
Cats; Dogs; Rabbits |
Approval status |
|
Approved - usually available as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
---|---|---|
|
Approved |
Chemical structure |
|
Aglepristone exhibits stereoisomerism, specifically geometric (cis-trans) and optical isomerism, due to its complex steroidal structure. The molecule contains multiple chiral centers, notably at positions 8, 11, 13, 14, and 17, which give rise to different enantiomers and diastereomers depending on the spatial arrangement of its atoms. In addition, the presence of a (1Z)-1-propenyl side chain at the 17-position introduces geometric isomerism, where the Z (cis) configuration is crucial for its biological activity. The pharmacologically active form of aglepristone is the (8S,11R,13S,14S,17R)-isomer. | |
---|---|---|
|
C₂₉H₃₇NO₂ | |
|
CC=CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O | |
|
C/C=C\[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O | |
|
RTCKAOKDXNYXEH-FWSJOHTJSA-N | |
|
InChI=1S/C29H37NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h5-7,9-10,15,17,24-26,32H,8,11-14,16,18H2,1-4H3/b15-5-/t24-,25+,26-,28-,29+/m0/s1 | |
|
Yes |
General status |
|
Steroid, Medicinal drug | |
---|---|---|
|
Unclassified substance | |
|
99% | |
|
dimethyl derivative, E-Isomer | |
|
Synthetic | |
|
Anti-progesterone activity | |
|
[Progesterone (P4) receptor, Antagonist] | |
|
124478-60-0 | |
|
685-671-3 | |
|
- | |
|
- | |
|
14153279 | |
|
Genito urinary system & sex hormones: Sex hormones and modulators of the genital system | |
|
QG03XB90 | |
|
No | |
|
- | |
|
431.61 | |
|
- | |
|
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-[(Z)-prop-1-enyl]-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one | |
|
(11β, 17α, Z)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propenyl)-estra-4,9-dien-3-one | |
|
- | |
|
- | |
|
- | |
|
Pale yellow oily liquid |
Commercial |
|
|
|||
---|---|---|---|---|
|
Current | |||
|
1992, veterinary clinical studies began; 2002, approved UK | |||
|
|
|||
|
|
|||
|
Usually supplied as an injectable solution | |||
|
Aglepristone is synthesised through a multi-step chemical process that builds its steroidal framework with precise stereochemistry to ensure high affinity for progesterone receptors. Structurally similar to mifepristone, aglepristone incorporates a (1Z)-1-propenyl side chain and multiple chiral centres, which are introduced via selective reactions such as hydroxylation, ketone formation, and alkylation. The production emphasizes stereoselectivity to yield the active (8S,11R,13S,14S,17R)-isomer, which is responsible for its antiprogestin activity. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
> 1000 | Q3 Q = Miscellaneous data from online sources Rat3 = Unverified data of known source |
Moderate | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class III) | - | - | ||||||||
|
> 1000 | Q3 Q = Miscellaneous data from online sources Rat3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Elimination occurs via the faeces, bile and to a lesser extent urine | R3 R = Peer reviewed scientific publications 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Harmful if injested or inhaled May cause restlessness, anorexia and gastrointestinal problems |
Handling issues |
|
|
|||
---|---|---|---|---|
|
No information available | |||
|
- | |||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
![]() |
|
|
||
---|---|---|---|
|
aglepristone | ||
|
aglepristone | ||
|
- | ||
|
- | ||
|
aglepristono | ||
|
aglepristona | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 12/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |